Cellaion Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Liquidation

Cellaion General Information

Description

Operator of a biotechnology firm intended to develop advanced therapies aiming to repair tissues and regenerate organs. The company generates products with specific targets in the field of inflammation and degenerative diseases to restore the human body's regenerative process and to support the survival of a failing native liver, enabling pharmaceutical companies to create treatments based on allogeneic adult liver stem cells.

Contact Information

Formerly Known As
Promethera
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • Watson and Crick Hill
  • Rue Granbonpré, 11
  • 1435 Mont-Saint-Guibert
  • Belgium
+32 010
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Watson and Crick Hill
  • Rue Granbonpré, 11
  • 1435 Mont-Saint-Guibert
  • Belgium
+32 010

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellaion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Bankruptcy: Liquidation 27-May-2024 Completed Bankruptcy: Liquidation
11. Later Stage VC 18-Jan-2023 Completed Clinical Trials - Phase 2
10. Secondary Transaction - Private Completed Clinical Trials - Phase 2
9. Later Stage VC 15-Feb-2022 Completed Clinical Trials - Phase 2
8. Later Stage VC 30-Jun-2021 Cancelled Clinical Trials - Phase 2
7. Later Stage VC (Series D) 09-Jan-2020 Completed Clinical Trials - Phase 2
6. Later Stage VC (Series C) 24-May-2017 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series C) 25-Nov-2014 Completed Startup
4. Grant 11-Mar-2014 $38.5M Completed Startup
3. Early Stage VC (Series B) 13-Jun-2013 $30.7M $38.5M Completed Startup
To view Cellaion’s complete valuation and funding history, request access »

Cellaion Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Class D
Class D
Class D
Class B
Class D
Class B
Class B
Preference 81,086 $125.31 $125.31 1x $125.31 8.48%
Class A 31,455 $104.43 $104.43 1x $104.43 3.29%
To view Cellaion’s complete cap table history, request access »

Cellaion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology firm intended to develop advanced therapies aiming to repair tissues and regenerate organs.
Drug Discovery
Mont-Saint-Guibert, Belgium
15 As of 2025

Madison, WI
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cellaion Competitors (56)

One of Cellaion’s 56 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Alentis Therapeutics Venture Capital-Backed Allschwil, Switzerland
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Sangamo Therapeutics Formerly VC-backed Richmond, CA
You’re viewing 5 of 56 competitors. Get the full list »

Cellaion Patents

Cellaion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4560009-A1 Method for the preparation of isolated liver-derived cells Inactive 27-Nov-2023
EP-3881853-A1 Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation Inactive 20-Mar-2020
AU-2020364951-A1 Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability Inactive 09-Oct-2019
CA-3156655-A1 Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability Pending 09-Oct-2019
EP-4041261-A1 Use of liver progenitor or stem cells, lysates thereof, and/or conditioned medium in disorders characterized by vascular hyperpermeability Inactive 09-Oct-2019 A61K35/407
To view Cellaion’s complete patent history, request access »

Cellaion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellaion Investments & Acquisitions (3)

Cellaion’s most recent deal was a Joint Venture with Aceso & Promethera (Joint Venture) for . The deal was made on 14-Jul-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aceso & Promethera (Joint Venture) 14-Jul-2020 Joint Venture Pharmaceuticals
Baliopharm 10-Apr-2018 Merger/Acquisition Drug Discovery
Cytonet 18-Apr-2016 Merger/Acquisition Biotechnology
To view Cellaion’s complete investments and acquisitions history, request access »

Cellaion Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Baliopharm Basel, Switzerland 2006

Cellaion FAQs

  • When was Cellaion founded?

    Cellaion was founded in 2009.

  • Where is Cellaion headquartered?

    Cellaion is headquartered in Mont-Saint-Guibert, Belgium.

  • What is the size of Cellaion?

    Cellaion has 15 total employees.

  • What industry is Cellaion in?

    Cellaion’s primary industry is Drug Discovery.

  • Is Cellaion a private or public company?

    Cellaion is a Private company.

  • What is Cellaion’s current revenue?

    The current revenue for Cellaion is .

  • How much funding has Cellaion raised over time?

    Cellaion has raised $169M.

  • Who are Cellaion’s competitors?

    Centrose, Marengo Therapeutics, Alentis Therapeutics, Inovio Pharmaceuticals, and Sangamo Therapeutics are some of the 56 competitors of Cellaion.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process